Bidirectional interactions of NK cells and dendritic cells in immunotherapy: Current and future perspective

Immunotherapy

Volumn 7, Issue 3, 2015, Pages 301-308

  Mahmood, Sajid ^a   Upreti, Deepak ^a   Sow, Ibrahim ^a   Amari, Abdulaziz ^a   Nandagopal, Saravanan ^a   Kung, Sam K P ^a  

^a Room 417 Apotex Center ^*  (Canada)

Author keywords

cell migration; dendritic cells; immune regulation; immunotherapy; natural killer cells

Indexed keywords

ANTIBODY;

BREAST ADENOCARCINOMA; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CELL DEATH; CELL INTERACTION; CELL MATURATION; CELL MIGRATION; CROSS PRESENTATION; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DNA MODIFICATION; EXOSOME; HUMAN; IMMUNOGENICITY; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE FUNCTION; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; ADAPTIVE IMMUNITY; ADOPTIVE IMMUNOTHERAPY; ANIMAL; CELL COMMUNICATION; CELL DIFFERENTIATION; IMMUNOLOGY; IMMUNOSURVEILLANCE; INNATE IMMUNITY; LYMPHOCYTE ACTIVATION; NEOPLASMS; PROCEDURES;

ADAPTIVE IMMUNITY; ANIMALS; CELL COMMUNICATION; CELL DIFFERENTIATION; DENDRITIC CELLS; HUMANS; IMMUNITY, INNATE; IMMUNOLOGIC SURVEILLANCE; IMMUNOTHERAPY, ADOPTIVE; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; NEOPLASMS;

EID: 84925739394     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.14.122     Document Type: Review

References (59)

1. Carotta S, Pang SH, Nutt SL, Belz GT. Identification of the earliest NK-cell precursor in the mouse BM. Blood 117, 5449-5452 (2011).
2. Cella M, Miller H Song C. Beyond NK cells: the expanding universe of innate lymphoid cells. Front. Immunol. 5, 282 (2014).
3. Tran J, Mahmood S, Carlyle JR, Kung SK. Altering the specificity of NK:target cell interactions by genetic manipulation of NK receptor expression on primary mouse NK cells. Vaccine 28, 3767-3772 (2010).
4. Fuchs A, Vermi W, Lee JS et al. Intraepithelial type 1 innate lymphoid cells are a unique subset of IL-12-and IL-15-responsive IFN-gamma-producing cells. Immunity 38, 769-781 (2013).
5. Wehner R, Dietze K, Bachmann M, Schmitz M. The bidirectional crosstalk between human dendritic cells and natural killer cells. J. Innate Immun. 3, 258-263 (2011).
6. Koch J, Steinle A, Watzl C, Mandelboim O. Activating natural cytotoxicity receptors of natural killer cells in cancer and infection. Trends Immunol. 34, 182-191 (2013).
7. Narni-Mancinelli E, Vivier E, Kerdiles YM. The 'T-cell-ness' of NK cells: unexpected similarities between NK cells and T cells. Int. Immunol. 23, 427-431 (2011).
8. Ham H, Billadeau DD. Human immunodeficiency syndromes affecting human natural killer cell cytolytic activity. Front. Immunol. 5, 2 (2014).
9. Iannello A, Raulet DH. Immune surveillance of unhealthy cells by natural killer cells. Cold Spring Harb. Symp. Quant. Biol. 78, 249-257 (2013).
10. Steinman RM. Decisions about dendritic cells: past, present, and future. Annu. Rev. Immunol. 30, 1-22 (2012).
11. Liu K, Nussenzweig MC. Origin and development of dendritic cells. Immunol. Rev. 234, 45-54 (2010).
12. Belz GT, Nutt SL. Transcriptional programming of the dendritic cell network. Nat. Rev. Immunol. 12, 101-113 (2012).
13. Fukaya T, Murakami R, Takagi H et al. Conditional ablation of CD205+ conventional dendritic cells impacts the regulation of T-cell immunity and homeostasis in vivo. Proc. Natl Acad. Sci. USA 109, 11288-11293 (2012).
14. Idoyaga J, Fiorese C, Zbytnuik L et al. Specialized role of migratory dendritic cells in peripheral tolerance induction. J. Clin. Invest. 123, 844-854 (2013).
15. Persson CM, Chambers BJ. Plasmacytoid dendritic cell-induced migration and activation of NK cells in vivo. Eur. J. Immunol. 40, 2155-2164 (2010).
16. Segura E, Amigorena S. Inflammatory dendritic cells in mice and humans. Trends Immunol. 34, 440-445 (2013).
17. Vanneman M, Dranoff G. Combining immunotherapy and targeted therapies in cancer treatment. Nat. Rev. Cancer 12, 237-251 (2012).
18. Anguille S, Smits EL, Lion E, van Tendeloo VF, Berneman ZN. Clinical use of dendritic cells for cancer therapy. Lancet Oncol. 15, e257-e267 (2014).
19. Carreno BM, Becker-Hapak M, Huang A et al. IL-12p70-producing patient DC vaccine elicits Tc1-polarized immunity. J. Clin. Invest. 123, 3383-3394 (2013).
20. Martin-Fontecha A, Thomsen LL, Brett S et al. Induced recruitment of NK cells to lymph nodes provides IFN-gamma for T(H)1 priming. Nat. Immunol. 5, 1260-1265 (2004).
21. Marcenaro E, Carlomagno S, Pesce S, Moretta A, Sivori S. NK/DC crosstalk in anti-viral response. Adv. Exp. Med. Biol. 946, 295-308 (2012).
22. Rizzello V, Bonaccorsi I, Dongarra ML, Fink LN, Ferlazzo G. Role of natural killer and dendritic cell crosstalk in immunomodulation by commensal bacteria probiotics. J. Biomed. Biotechnol. 2011, 473097 (2011).
23. Kirchberger S, Royston DJ, Boulard O et al. Innate lymphoid cells sustain colon cancer through production of interleukin-22 in a mouse model. J. Exp. Med. 210, 917-931 (2013).
24. Morandi B, Mortara L, Chiossone L et al. Dendritic cell editing by activated natural killer cells results in a more protective cancer-specific immune response. PLoS ONE 7, e39170 (2012).
25. Batalla EI, Pino Martinez AM, Poncini CV et al. Impairment in natural killer cells editing of immature dendritic cells by infection with a virulent Trypanosoma cruzi population. J. Innate Immun 5, 494-504 (2013).
26. Laffont S, Seillet C, Ortaldo J, Coudert JD, Guery JC. Natural killer cells recruited into lymph nodes inhibit alloreactive T-cell activation through perforin-mediated killing of donor allogeneic dendritic cells. Blood 112, 661-671 (2008).
27. Ferlazzo G, Morandi B. Cross-talks between natural killer cells and distinct subsets of dendritic cells. Front. Immunol. 5, 159 (2014).
28. Zanoni I, Granucci F, Foti M, Ricciardi-Castagnoli P. Self-tolerance, dendritic cell (DC)-mediated activation and tissue distribution of natural killer (NK) cells. Immunol. Lett. 110, 6-17 (2007).
29. Draghi M, Pashine A, Sanjanwala B et al. NKp46 and NKG2D recognition of infected dendritic cells is necessary for NK cell activation in the human response to influenza infection. J. Immunol. 178, 2688-2698 (2007).
30. Vujanovic L, Szymkowski DE, Alber S, Watkins SC, Vujanovic NL, Butterfield LH. Virally infected and matured human dendritic cells activate natural killer cells via cooperative activity of plasma membrane-bound TNF and IL-15. Blood 116, 575-583 (2010).
31. Romee R, Leong JW, Fehniger TA. Utilizing cytokines to function-enable human NK cells for the immunotherapy of cancer. Scientifica (Cairo) 2014, 205796 (2014).
32. Van Elssen CH, Vanderlocht J, Oth T, Senden-Gijsbers BL, Germeraad WT, Bos GM. Inflammation-restraining effects of prostaglandin E2 on natural killer-dendritic cell (NK-DC) interaction are imprinted during DC maturation. Blood 118, 2473-2482 (2011).
33. Harizi H. Reciprocal crosstalk between dendritic cells and natural killer cells under the effects of PGE2 in immunity and immunopathology. Cell Mol. Immunol. 10, 213-221 (2013).
34. Simhadri VL, Hansen HP, Simhadri VR et al. A novel role for reciprocal CD30-CD30L signaling in the cross-talk between natural killer and dendritic cells. Biol. Chem. 393, 101-106 (2012).
35. Fernandez NC, Lozier A, Flament C et al. Dendritic cells directly trigger NK cell functions: cross-talk relevant in innate anti-tumor immune responses in vivo. Nat. Med. 5, 405-411 (1999).
36. Catucci M, Zanoni I, Draghici E et al. Wiskott-Aldrich syndrome protein deficiency in natural killer and dendritic cells affects antitumor immunity. Eur. J. Immunol. 44, 1039-1045 (2014).
37. Romagnani C, Babic M. NK/DC crosstalk in immunosurveillance: a broken relationship caused by WASP-deficiency. Eur. J. Immunol. 44, 958-961 (2014).
38. Wei J, Xia S, Sun H et al. Critical role of dendritic cell-derived IL-27 in antitumor immunity through regulating the recruitment and activation of NK and NKT cells. J. Immunol. 191, 500-508 (2013).
39. Shimizu K, Fujii S. DC therapy induces long-term NK reactivity to tumors via host DC. Eur. J. Immunol. 39, 457-468 (2009).
40. Bouwer AL, Saunderson SC, Caldwell FJ et al. NK cells are required for dendritic cell-based immunotherapy at the time of tumor challenge. J. Immunol. 192, 2514-2521 (2014).
41. Srivastava RM, Lee SC, Andrade Filho PA et al. Cetuximab-activated natural killer and dendritic cells collaborate to trigger tumor antigen-specific T-cell immunity in head and neck cancer patients. Clin. Cancer Res. 19, 1858-1872 (2013).
42. Deauvieau F, Ollion V, Doffin AC et al. Human natural killer cells promote cross-presentation of tumor cell-derived antigens by dendritic cells. Int. J. Cancer doi:10.1002/ ijc.29087 (2014) (Epub ahead of print).
43. Tomihara K, Kato K, Masuta Y et al. Gene transfer of the CD40-ligand to human dendritic cells induces NK-mediated antitumor effects against human carcinoma cells. Int. J. Cancer 120, 1491-1498 (2007).
44. Boudreau JE, Bonehill A, Thielemans K, Wan Y. Engineering dendritic cells to enhance cancer immunotherapy. Mol. Ther. 19, 841-853 (2011).
45. Naveh HP, Vujanovic L, Butterfield LH. Cellular immunity induced by a recombinant adenovirus-human dendritic cell vaccine for melanoma. J. Immunother. Cancer 1, 19 (2013).
46. Boudreau JE, Stephenson KB, Wang F et al. IL-15 and type I interferon are required for activation of tumoricidal NK cells by virus-infected dendritic cells. Cancer Res. 71, 2497-2506 (2011).
47. Brandstadter JD, Huang X, Yang Y. NK cell-extrinsic IL-18 signaling is required for efficient NK-cell activation by vaccinia virus. Eur. J. Immunol. 44, 2659-2666 (2014).
48. Kubler K, tho Pesch C, Gehrke N et al. Immunogenic cell death of human ovarian cancer cells induced by cytosolic poly(I:C) leads to myeloid cell maturation and activates NK cells. Eur. J. Immunol. 41, 3028-3039 (2011).
49. Wong JL, Muthuswamy R, Bartlett DL, Kalinski P. IL-18-based combinatorial adjuvants promote the intranodal production of CCL19 by NK cells and dendritic cells of cancer patients. Oncoimmunology 2, e26245 (2013).
50. Wong JL, Berk E, Edwards RP, Kalinski P. IL-18-primed helper NK cells collaborate with dendritic cells to promote recruitment of effector CD8+ T cells to the tumor microenvironment. Cancer Res 73, 4653-4662 (2013).
51. Nguyen-Pham TN, Yang DH, Nguyen TA et al. Optimal culture conditions for the generation of natural killer cell-induced dendritic cells for cancer immunotherapy. Cell Mol. Immunol. 9, 45-53 (2012).
52. Shifrin DA, Jr, Demory Beckler M, Coffey RJ, Tyska MJ. Extracellular vesicles: communication, coercion, and conditioning. Mol. Biol. Cell 24, 1253-1259 (2013).
53. Reiners KS, Dassler J, Coch C, Pogge von Strandmann E. Role of exosomes released by dendritic cells and/or by tumor targets: regulation of NK cell plasticity. Front. Immunol. 5, 91 (2014).
54. Viaud S, Terme M, Flament C et al. Dendritic cell-derived exosomes promote natural killer cell activation and proliferation: a role for NKG2D ligands and IL-15Ralpha. PLoS ONE 4, e4942 (2009).
55. Vitale M, Cantoni C, Pietra G, Mingari MC, Moretta L. Effect of tumor cells and tumor microenvironment on NK-cell function. Eur. J. Immunol. 44, 1582-1592 (2014).
56. Takamatsu H, Okuno T, Kumanogoh A. Regulation of immune cell responses by semaphorins and their receptors. Cell. Mol. Immunol. 7, 83-88 (2010).
57. Roney K, Holl E, Ting J. Immune plexins and semaphorins: old proteins, new immune functions. Protein Cell 4, 17-26 (2013).
58. Holl EK, Roney KE, Allen IC et al. Plexin-B2 and Plexin-D1 in dendritic cells: expression and IL-12/IL-23p40 production. PLoS ONE 7, e43333 (2012).
59. Mahmood S, Nandagopal S, Sow I, Lin F, Kung SK. Microfluidic-based, live-cell analysis allows assessment of NK-cell migration in response to crosstalk with dendritic cells. Eur. J. Immunol. 44, 2737-2748 (2014).